Navigation Links
Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR
Date:10/8/2008

ams; our planned Phase 2 clinical studies and the ability of those studies to successfully evaluate HspE7 as a potential treatment for CIN 1 and CIN 2/3; the structure and location of our planned Phase 2 trials; completion of the second protocol for CIN 1; potential uses for Poly-ICR; our ability to advance Poly-ICR resulting in revenue generation and internal development; the ability of Poly-ICR to provide us with near-term revenue opportunity; the development of Poly-ICR for treatment of GW and actinic keratosis; completion of development activities and the filing of an IND application in connection with Poly-ICR; finalizing manufacturing and formulation protocols and filing an IND in connection with Hsp 6/11; execution of our corporate restructuring as planned; our ability to retain key personnel; and our plan to expand corporate development efforts and the potential results of such efforts.

Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments to be materially different from results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, the possibility that our planned corporate restructuring will not have the anticipated affect; that we will not succeed in forming strategic alliances and, if we do, the possibility that such alliances will not allow us to realize the greatest value for our programs; that we will not commence Phase 2 clinical studies as planned and, if we do, that such studies will not support the use of HspE7 as a treatment for CIN 1 or CIN 2/3; that we will not complete the second protocol for the CIN 1 indication; that Poly-IRC will not be useful as a broad immune stimulatory agent or vaccine adjuvant; that we will not be able to advance Poly-ICR to generate revenue or for internal development; that Poly-ICR will not provide us with near-term reve
'/>"/>

SOURCE Nventa Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Nventa Appoints John Varian to Board of Directors
9. Nventa Appoints Gordon H. Busenbark to Board of Directors
10. CardioDynamics Provides 2007 Shareholder Meeting Update
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... BOSTON, MA (PRWEB) September 30, 2014 ... company, SoundConnect announces four new-hosted collaboration ... innovative bundles deliver high quality conferencing experiences for ... collaboration packages to choose from, businesses have optimized ... bundled solutions include audio only minutes ...
(Date:10/1/2014)... Industry leaders from retail ... around the theme, ,Commercial Opportunities in the Era of ... Elsevier , a world-leading provider of scientific, ... a gathering of some of the industry,s most prominent ... today and in the future. The Elsevier ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... - 2014 Summary Global Markets Direct,s, ... - 2014, provides an overview of the Pacific ... This report provides comprehensive information on the ... LLC,s, complete with comparative analysis at various stages, ...
(Date:9/30/2014)... Proove Biosciences , the commercial and research leader ... genetic test built upon research from their published P.A.I.N. ... provide physicians with an objective way to understand theirs ... between individuals. With this new test, physicians will be ... predisposition that will affect their pain tolerance. , The ...
Breaking Biology Technology:SoundConnect Launches New Audio, Web and Video Bundles 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3
... ATLANTA, April 1, 2008 Piedmont Heart Institute ... 20-member cardiovascular,physician practice, Cardiology of Georgia, P.C. (COG), ... 1, 2008. With eight,locations including Buckhead, Canton, Fayetteville ... practice under the Piedmont Heart Institute and an,important ...
... April 1, 2008 ,Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: ... M. Loar has been appointed Chief,Financial Officer. Mr. Loar ... Loar joins the company from Osteologix, where he has ... a proven track record as a chief financial officer, ...
... LONDON, April 1, 2008 Plethora Solutions Holdings ... for the,treatment and management of urological disorders, today ... financing agreement with Paul Capital,Healthcare. Through this agreement, ... with $15 million payable upon signature and a ...
Cached Biology Technology:Piedmont Heart Institute Welcomes Cardiology of Georgia 2Piedmont Heart Institute Welcomes Cardiology of Georgia 3Piedmont Heart Institute Welcomes Cardiology of Georgia 4Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer 2Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer 3Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment 2Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment 3Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment 4
(Date:9/30/2014)... Ocean Health Index rates the Earth,s oceans at ... addition, for the first time, the report assessed ... national jurisdiction (high-seas areas) all critical regions ... providing sustainable food sources. , In the third ... by scientists from UC Santa Barbara,s National Center ...
(Date:9/30/2014)... Calif. The National Institutes of Health (NIH) ... today to develop an electrode array system that ... brain works through unprecedented resolution and scale. , ... to support President Obama,s BRAIN (Brain Research ... research effort to revolutionize our understanding of the ...
(Date:9/30/2014)... drinking water may increase the risk of stillbirth ... led by a Boston University School of Public ... journal Environmental Health , compared 1,091 PCE-exposed ... in Cape Cod, Ma., where water was contaminated ... by the installation of vinyl-lined asbestos cement pipes. ...
Breaking Biology News(10 mins):Rating the planet's oceans 2Rating the planet's oceans 3NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3Contaminated water linked to pregnancy complications, BU study finds 2
... - Rainfall data from a NASA satellite show that summertime ... than on weekends. Scientists say air pollution from humans is ... and the day of the week is evident in data ... Midweek storms tend to be stronger, drop more rain and ...
... has demonstrated the role of a gene important to ... that requires coordination of differentiation of immature neural cells ... numbers. Until now, the mechanisms regulating these distinct cellular ... will be published in the Feb. 15 issue of ...
... 2008 -- As organic farming becomes more common, ... increasingly important. In a recent study in Journal ... discrimination to determine if non-organic, synthetic fertilizers were ... the Instituto Murciano de Investigacin y Desarrollo Agrario ...
Cached Biology News:NASA data link pollution to rainy summer days in the southeast 2NASA data link pollution to rainy summer days in the southeast 3Trainor Lab characterizes gene essential for prenatal development of nervous system 2Is it organic or not? 2
... sizing single-stranded RNA ranging from 0.5 kb to 10 ... consists of nine bands in even increments (0.5 1 ... to simplify size estimation. The 1.5 kb band is ... and identification of RNA bands on the gel. All ...
Recombinant Mouse Wnt-3a...
Homo sapiens jumping translocation breakpoint...
One-step, microplate or cuvet, colorimetric, detection range 0.01 g/dL to 5 g/dL. Procedure: 5 min....
Biology Products: